Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.
Thermo Fisher Buys Mesa Biotech
Acquisitions, Business, COVID-19 Testing, Emergency Use Authorization (EUA), FDA, Haemophilus influenza type B, Infectious Diseases, Influenza A, Milestone Payments, Molecular Diagnostics, Point-Of-Care Devices, Respiratory Syncytial Virus (RSV) Infection, SARS-CoV-2 virusThermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.
Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
Acquisitions, Analysts, Business, Charcot–Marie–Tooth Disease (CMT), Depression, Essential Tremor, Major Depressive Disorder (MDD), Milestone Payments, Neurological Disorders, Postpartum Depression, Potential Blockbusters, Product Pipeline, Shares, U.S. Centers for Disease Control and PreventionBiogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.
With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
Sanofi Pasteur and Lexington, Massachusetts-based Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases.